HONG KONG UNDERWRITING AGREEMENT relating to a public offering in Hong Kong of initially 5,904,000 Shares of nominal value of US$0.0001 per Share in the capital of BeiGene, Ltd., being part of a global offering of initially 65,600,000 SharesUnderwriting Agreement • August 1st, 2018 • BeiGene, Ltd. • Pharmaceutical preparations • Hong Kong
International Offering only), CICC, DB, UBS are acting as joint bookrunners and CRS is acting as a lead manager of the Global Offering.
